Autolus Therapeutics Submits Fiscal Year 2018 Form 20-F

LONDON, Nov. 23, 2018 /PRNewswire/ -- Autolus Therapeutics plc (NASDAQ: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it has filed its annual report on Form 20-F for the fiscal year ended 2018 with the United States Securities and Exchange Commission. The annual report can be found on Autolus' investor relations website at https://www.autolus.com/investor-relations/financial-information/sec-filings.

About Autolus Therapeutics plc
Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. For more information, go to: https://www.autolus.com

 

Investor contact:

 

International Media Contact:

 

U.S. Media Contact:  

S.A. Noonan Communications

 

JW Communications

 

Rx Communications Group, LLC

Susan A. Noonan

 

Julia Wilson

 

Paula Schwartz

+1-212-966-3650

 

+44 (0)7818 430877

 

+ 1-917-322-2216

susan@sanoonan.com

 

juliawilsonuk@gmail.com

 

pschwartz@rxir.com

         
         

 

 

Cision View original content:http://www.prnewswire.com/news-releases/autolus-therapeutics-submits-fiscal-year-2018-form-20-f-300754699.html

SOURCE Autolus Therapeutics plc

   
Company Codes: NASDAQ-NMS:AUTL  

Back to news